Is Eli Lilly and Company (LLY) a Buy, Sell, or Hold?
Eli Lilly and Company
NYSE:LLY
$1152.54004 USD
-$29.33 (-2.48%)
- Volume
- 2.64M
- Average Volume
- 3.28M
- Market Capitalization
- $1.09T
- P/E Ratio
- 40.87
- Dividend Yield
- 0.56%
- Price Target
- $1300.00
- Year High
- $1249.45
- Year Low
- $623.78
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.22
- Current Ratio
- $1.50
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | David A. Ricks |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Current Symbol | LLY |
| CUSIP | 532457108 |
| CIK | 0000059478 |
| Web | https://www.lilly.com |
| Phone | 317 276 2000 |
| Currency | USD |
| Employees | 50000 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.39 |
| Payout Ratio | 0.22 |
| Current Ratio | 1.50 |
| Quick Ratio | 1.10 |
| Cash Ratio | 0.14 |
Sales & Book Value
| Annual Sales | $65.18B |
| Price / Sales | 15.02 |
| Cash Flow | 15.18 |
| Price / Cash Flow | 79.93 |
| Price / Book | 33.05 |
Price Target and Rating
| Average Stock Price Forecast | $1300.00 |
| High Stock Price Forecast | $1500.00 |
| Low Stock Price Forecast | $1135.00 |
| Forecast Upside/Downside | -11.34% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 45 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $22.95 |
| Trailing P/E Ratio | 40.87 |
| PEG Ratio | 0.32 |
| P/E Growth | 0.32 |
| Net Income | $20.64B |
| Net Margin | 34.98% |
| Pretax Margin | 43.08% |
| Return on Equity | 101.30% |
| Return on Assets | 21.68% |
Financials Score
| AltmanZ Score | 9.91 |
| Piotroski Score | 6.00 |
| Working Capital | 18.2B |
| Total Assets | 116.58B |
| Ebit | 31.86B |
| Market Cap | 1.12T |
| Total Liabilities | 85.38B |
Poll Results
About Eli Lilly and Company (NYSE:LLY) Stock
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metasta ... tic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
2026-07-14 20:00:00
The market leader in obesity shots, Lilly hasn't made a major dent in the pill market yet.
Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
2026-07-14 18:45:22
Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -2.48% change compared to its last close.
Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge
2026-07-14 10:56:28
JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.
Is Lilly Stock On Track To Hit $2,090?
2026-07-14 10:30:06
This article was written by Doug Nathman, with research by his team at Trefis.
Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?
2026-07-14 06:10:00
Eli Lilly is the leader in the weight loss drug market -- a market on track to reach almost $100 billion. The company's weight loss drugs have delivered tremendous growth in recent years.
Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher
2026-07-13 14:00:35
Eli Lilly (NYSE:LLY | LLY Price Prediction) has whipsawed shareholders in 2026, but the setup heading into the second half looks compelling.
2026-07-13 08:49:22
Eli Lilly and Company (NYSE:LLY) shares are in the spotlight Monday as the company presents new data at the Alzheimer's Association International Conference in London. Wall Street weighed in on the stock last week.
Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors
2026-07-13 04:23:00
Mounjaro and Zepbound combined for $12.8 billion of Lilly's $19.8 billion in first-quarter revenue. Worldwide Mounjaro revenue jumped 125% year over year in the first quarter.
Frequently Asked Questions
-
What is the current Eli Lilly and Company (LLY) stock price?
-
Eli Lilly and Company(NYSE:LLY) stock price is $1152.54004 in the last trading session. During the trading session, LLY stock reached the peak price of $1249.45 while $623.78 was the lowest point it dropped to. The percentage change in LLY stock occurred in the recent session was --2.48% while the dollar amount for the price change in LLY stock was -$-29.33.
-
LLY's industry and sector of operation?
-
The NYSE listed LLY is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of LLY?
-
Daniel Skovronsky | Chief Scientific & Product Officer and President of Lilly Research Laboratories
David A. Ricks | Chairman & CEO
Diogo Rau | Executive VP and Chief Information & Digital Officer
Donald A. Zakrowski | Senior Vice President of Finance & Chief Accounting Officer
Eric Dozier | Executive Vice President & Chief People Officer -
How many employees does LLY have?
-
Number of LLY employees currently stands at 50000. LLY operates from Lilly Corporate Center, Indianapolis, IN 46285, US.
-
Link for LLY official website?
-
Official Website of LLY is: https://www.lilly.com
-
How do I contact LLY?
-
LLY could be contacted at phone #317 276 2000 and can also be accessed through its website. LLY operates from Lilly Corporate Center, Indianapolis, IN 46285, US.
-
How many shares of LLY are traded daily?
-
The average number of LLY shares traded daily for last 3 months was 3.28M.
-
What is the market cap of LLY currently?
-
The market value of LLY currently stands at $1.09T with its latest stock price at $1152.54004